Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation
{{output}}
Aims of the study: Marketing authorisation of the bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) for maternal vaccination was predominantly based on safety and efficacy findings from the pivotal ... ...
